Zevra Therapeutics, Inc. (ZVRA) Misses Q3 EPS by 28c

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q3 EPS of ($0.69), $0.28 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $3.69 million versus the consensus estimate of $4.87 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• Bernstein on China Online Beauty: Very Weak July Performance